Novel approaches for RNA interference and their application in cancer therapy

Current Pharmacogenomics

Volumn 2, Issue 4, 2004, Pages 313-324

  Berletch, Joel B ^a   Green, Jessica ^a   Cunningham, Amanda P ^a   Andrews, Lucy G ^a   Tollefsbol, Trygve O ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Cancer therapy; Double stranded RNA (dsRNA); RNA interference (RNAi); Small interfering RNA (siRNA)

Indexed keywords

ANTIBIOTIC AGENT; DOUBLE STRANDED RNA; IMATINIB; MESSENGER RNA; NUCLEOTIDE; PLASMID VECTOR; RETROVIRUS VECTOR; SINGLE STRANDED DNA; SMALL INTERFERING RNA;

CANCER RESEARCH; CANCER RESISTANCE; CANCER THERAPY; DESTRUCTION; DOWN REGULATION; DRUG DEVELOPMENT; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG SYNTHESIS; GENE ACTIVITY; GENE DELIVERY SYSTEM; GENE EXPRESSION; GENE TARGETING; GENE TECHNOLOGY; GENE VECTOR; HOST RESISTANCE; HUMAN; KNOCKOUT GENE; LEUKEMIA; MAMMAL; MOLECULAR SIZE; MULTIDRUG RESISTANCE; NONHUMAN; POSTTRANSCRIPTIONAL GENE SILENCING; REVIEW; RNA DEGRADATION; RNA INTERFERENCE; SEQUENCE HOMOLOGY; TREATMENT OUTCOME; VIRUS INFECTION;

MAMMALIA;

EID: 9444266427     PISSN: 15701603     EISSN: None     Source Type: Journal    
DOI: 10.2174/1570160043377321     Document Type: Review

References (80)

1. Alter, M. J. (1997) Epidemiology of hepatitis C. Hepatology 26, 62S-65S.
2. Alvarez, R. D.; Barnes, M. N.; Gomez-Navarro, J.; Wang, M.; Strong, T. V.; Arafat, W.; Arani, R. B.; Johnson, M. R.; Roberts, B. L.; Siegal, G. P. and Curiel, D. T. (2000) A cancer gene therapy approach utilizing an anti-erbB-2 single-chain antibody-encoding adenovirus (AD21): a phase I trial. Clin. Cancer Res. 6, 3081-3087.
3. Arenz, C. and Schepers, U. (2003) RNA interference: from an ancient mechanism to a state of the art therapeutic application? Naturwissenschaften 90, 345-359.
4. Barnett, B. G.; Crews, C. J. and Douglas, J. T. (2002) Targeted adenoviral vectors. Biochim. Biophys. Acta 1575, 1-14.
5. Barton, G. M. and Medzhitov, R. (2002) Retroviral delivery of small interfering RNA into primary cells. Proc. Natl. Acad. Sci. USA 99, 14943-14945.
6. Berns, K.; Hijmans, E. M.; Mullenders, J.; Brummelkamp, T. R.; Velds, A.; Heimerikx, M.; Kerkhoven, R. M.; Madiredjo, M.; Nijkamp, W.; Weigelt, B.; Agami, R.; Ge, W.; Cavet, G.; Linsley, P. S.; Beijersbergen, R. L. and Bernards, R. (2004) A large-scale RNAi screen in human cells identifies new components of the p53 pathway. Nature 428, 431-437.
7. Biedler, J. L. and Riehm, H. (1970) Cellular resistance to actinomycin D in Chinese hamster cells in vitro: cross-resistance, radioautographic, and cytogenetic studies. Cancer Res. 30, 1174-1184.
8. Bosch, F. X.; Manos, M. M.; Munoz, N.; Sherman, M.; Jansen, A. M.; Peto, J.; Schiffman, M. H.; Moreno, V.; Kurman, R. and Shah, K. V. (1995) Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J. Natl. Cancer Inst. 87, 796-802.
9. Brummelkamp, T. R.; Bernards, R. and Agami, R. (2002a) A system for stable expression of short interfering RNAs in mammalian cells. Science 296, 550-553.
10. Brummelkamp, T. R.; Bernards, R. and Agami, R. (2002b) Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell 2, 243-247.
11. Butz, K.; Ristriani, T.; Hengstermann, A.; Denk, C.; Scheffner, M. and Hoppe-Seyler, F. (2003) siRNA targeting of the viral E6 oncogene efficiently kills human papillomavirus-positive cancer cells. Oncogene 22, 5938-5945.
12. Casey, B. P. and Glazer, P. M. (2001) Gene targeting via triple-helix formation. Prog. Nucleic Acid Res. Mol. Biol. 67 163-192.
13. Chiu, Y. L. and Rana, T. M. (2002) RNAi in human cells: basic structural and functional features of small interfering RNA. Mol. Cell. 10, 549-561.
14. Crystal, R. G.; McElvancy, N. G.; Rosenfeld, M. A.; Chu, C. S.; Mastrangeli, A.; Hay, J. G.; Brody, S. L.; Jaffe, H. A.; Eissa, N. T. and Danel, C. (1994) Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis. Nat. Genet. 8, 42-51.
15. Dean, N. M. (2001) Functional genomics and target validation approaches using antisense oligonucleotide technology. Curr. Opin. Biotechnol. 12, 622-625.
16. Devroe, E. and Silver, P. A. (2002) Retrovirus-delivered siRNA. BMC Biotechnol. 2, 15.
17. Dirac, A. M. and Bernards, R. (2003) Reversal of senescence in mouse fibroblasts through lentiviral suppression of p53. J. Biol. Chem. 278, 11731-11734.
18. Dobrovic, A.; Morley, A. A.; Seshadri, R. and Januszewicz, E. H. (1991) Molecular diagnosis of Philadelphia negative CML using the polymerase chain reaction and DNA analysis: clinical features and course of M-bcr negative and M-bcr positive CML. Leukemia 5, 187-190.
19. Donze, O. and Picard, D. (2002) RNA interference in mammalian cells using siRNAs synthesized with T7 RNA polymerase. Nucleic Acids Res. 30, e46.
20. Druker, B. J.; Sawyers, C. L.; Kantarjian, H.; Resta, D. J.; Reese, S. F.; Ford, J. M.; Capdeville, R. and Talpaz, M. (2001) Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N. Engl. J. Med. 344, 1038-1042.
21. Druker, B. J.; Talpaz, M.; Resta, D. J.; Peng, B.; Buchdunger, E.; Ford, J. M.; Lydon, N. B.; Kantarjian, H.; Capdeville, R.; Ohno-Jones, S. and Sawyers, C. L. (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344, 1031-1037.
22. Druker, B. J.; Tamura, S.; Buchdunger, E.; Ohno, S.; Segal, G. M.; Fanning, S.; Zimmermann, J. and Lydon, N. B. (1996) Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med. 2, 561-566.
23. Elbashir, S. M.; Harborth, J.; Lendeckel, W.; Yalcin, A.; Weber, K. and Tuschl, T. (2001) Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411, 494-498.
24. Elbashir, S. M.; Harborth, J.; Weber, K. and Tuschl, T. (2002) Analysis of gene function in somatic mammalian cells using small interfering RNAs. Methods 26, 199-213.
25. Fire, A.; Xu, S.; Montgomery, M. K.; Kostas, S. A.; Driver, S. E. and Mello, C. C. (1998) Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391, 806-811.
26. Goldman, J. M. and Druker, B. J. (2001) Chronic mycloid leukemia: current treatment options. Blood 98, 2039-2042.
27. Grzmil, M.; Thelen, P.; Hemmerlein, B.; Schweyer, S.; Voigt, S.; Mury, D. and Burfeind, P. (2003) Bax inhibitor-1 is overexpressed in prostate cancer and its specific down-regulation by RNA interference leads to cell death in human prostate carcinoma cells. Am. J. Pathol. 163, 543-552.
28. Guo, S. and Kemphues, K. J. (1995) par-1, a gene required for establishing polarity in C. elegans embryos, encodes a putative Ser/Thr kinase that is asymmetrically distributed. Cell 81, 611-620.
29. Hall, A. H. and Alexander, K. A. (2003) RNA interference of human papillomavirus type 18 E6 and E7 induces senescence in HeLa cells. J. Virol. 77, 6066-6069.
30. Hamada, M.; Ohtsuka, T.; Kawaida, R.; Koizumi, M.; Morita, K.; Furukawa, H.; Imanishi, T.; Miyagishi, M. and Taira, K. (2002) Effects on RNA interference in gene expression (RNAi) in cultured mammalian cells of mismatches and the introduction of chemical modifications at the 3′-ends of siRNAs. Antisense Nucleic Acid Drug Dev. 12, 301-309.
31. Harborth, J.; Elbashir, S. M.; Bechert, K.; Tuschl, T. and Weber, K. (2001) Identification of essential genes in cultured mammalian cells using small interfering RNAs. J. Cell Sci. 114, 4557-4565.
32. Harley, C. B. (2002) Telomerase is not an oncogene. Oncogene 21, 494-502.
33. Heidenreich, O.; Krauter, J.; Riehle, H.; Hadwiger, P.; John, M.; Heil, G.; Vornlocher, H.P. and Nordheim, A. (2003) AML1/MTG8 oncogene suppression by small interfering RNAs supports myeloid differentiation of t(8;21)-positive leukemic cells. Blood 101, 3157-3163.
34. Irie, N.; Sakai, N.; Ueyama, T.; Kajimoto, T.; Shirai, Y. and Saito, N. (2002) Subtype- and species-specific knockdown of PKC using short interfering RNA. Biochem. Biophys. Res. Commun. 298, 738-743.
35. Kantarjian, H.; Sawyers, C.; Hochhaus, A.; Guilhot, F.; Schiffer, C.; Gambacorti-Passerini, C.; Niederwieser, D.; Resta, D.; Capdeville, R.; Zoellner, U.; Talpaz, M.; Druker, B.; Goldman, J.; O'Brien, S. G.; Russell, N.; Fischer, T.; Ottmann, O.; Cony-Makhoul, P.; Facon, T.; Stone, R.; Miller, C.; Tallman, M.; Brown, R.; Schuster, M.; Loughran, T.; Gratwohl, A.; Mandelli, F.; Saglio, G.; Lazzarino, M.; Russo, D.; Baccarani, M. and Morra, E. (2002) Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N. Engl. J. Med. 346, 645-652.
36. Kosciolek, B. A.; Kalantidis, K.; Tablet, M. and Rowley, P. T. (2003) Inhibition of telomerase activity in human cancer cells by RNA interference. Mol. Cancer Ther. 2, 209-216.
37. Leirdal, M. and Sioud, M. (2002) Gene silencing in mammalian cells by preformed small RNA duplexes. Biochem. Biophys. Res. Commun. 295, 744-748.
38. Lugo, T. G.; Pendergast, A. M.; Muller, A. J. and Witte, O. N. (1990) Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 247, 1079-1082.
39. Mantovani, F. and Banks, L. (2001) The human papillomavirus E6 protein and its contribution to malignant progression. Oncogene 20, 7874-7887.
40. Masutomi, K.; Yu, E. Y.; Khurts, S.; Ben-Porath, I.; Currier, J. L.; Metz, G. B.; Brooks, M. W.; Kaneko, S.; Murakami, S.; DeCaprio, J. A.; Weinberg, R. A.; Stewart, S. A. and Hahn, W. C. (2003) Telomerase maintains telomere structure in normal human cells. Cell 114, 241-253.
41. Maurer, J.; Janssen, J. W.; Thiel, E.; van Denderen, J.; Ludwig, W. D.; Aydemir, U.; Heinze, B.; Fonatsch, C.; Harbott, J.; Reiter, A. and et al. (1991) Detection of chimeric BCR-ABL genes in acute lymphoblastic leukaemia by the polymerase chain reaction. Lancet 337, 1055-1058.
42. Miyagishi, M.; Hayashi, M. and Taira, K. (2003) Comparison of the suppressive effects of antisense oligonucleotides and siRNAs directed against the same targets in mammalian cells. Antisense Nucleic Acid Drug Dev. 13, 1-7.
43. Miyoshi, H.; Kozo, T.; Shimizu, K.; Enomoto, K.; Maseki, N.; Kaneko, Y.; Kamada, N. and Ohki, M. (1993) The t(8;21) translocation in acute myeloid leukemia results in production of an AML1-MTG8 fusion transcript. EMBO J. 12, 2715-2721.
44. Mo, Y.; Gan, Y.; Song, S.; Johnston, J.; Xiao, X.; Wientjes, M. G. and Au, J. L. (2003) Simultaneous targeting of telomeres and telomerase as a cancer therapeutic approach. Cancer Res. 63, 579-585.
45. Munger, K.; Basile, J. R.; Duensing, S.; Eichten, A.; Gonzalez, S. L.; Grace, M. and Zacny, V. L. (2001) Biological activities and molecular targets of the human papillomavirus E7 oncoprotein. Oncogene 20, 7888-7898.
46. Munger, K.; Phelps, W. C.; Bubb, V.; Howley, P. M. and Schlegel, R. (1989) The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes. J. Virol. 63, 4417-4421.
47. Nieth, C.; Priebsch, A.; Stege, A. and Lage, H. (2003) Modulation of the classical multidrug resistance (MDR) phenotype by RNA interference (RNAi). FEBS Lett. 545, 144-150.
48. Okuda, T.; Cai, Z.; Yang, S.; Lenny, N.; Lyu, C. J.; van Deursen, J. M.; Harada, H. and Downing, J. R. (1998) Expression of a knocked-in AML1-ETO leukemia gene inhibits the establishment of normal definitive hematopoiesis and directly generates dysplastic hematopoietic progenitors. Blood 91, 3134-3143.
49. Plasterk, R. H. (2002) RNA silencing: the genome's immune system. Science. 296, 1263-1265.
50. Rahman, M. M.; Miyamoto, H.; Lardy, H. and Chang, C. (2003) Inactivation of androgen receptor coregulator ARA55 inhibits androgen receptor activity and agonist effect of antiandrogens in prostate cancer cells. Proc. Natl. Acad. Sci. USA 100, 5124-5129.
51. Rubinson, D. A.; Dillon, C. P.; Kwiatkowski, A. V.; Sievers, C.; Yang, L.; Kopinja, J.; Rooney, D. L.; Ihrig, M. M.; McManus, M. T.; Gertler, F. B.; Scott, M. L. and Van Parijs, L. (2003) A lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference. Nat. Genet. 33 401-406.
52. Rust, C. and Gores, G, J. (2000) Apoptosis and liver disease. Am. J. Med. 108, 567-574.
53. Seo, M. Y.; Abrignani, S.; Houghton, M. and Han, J. H. (2003) Small interfering RNA-mediated inhibition of hepatitis C virus replication in the human hepatoma cell line Huh-7. J. Virol. 77 810-812.
54. Shay, J. W. and Bacchetti, S. (1997) A survey of telomerase activity in human cancer. Eur. J. Cancer 33, 787-791.
55. Shi, Y. (2003) Mammalian RNAi for the masses. Trends Genet. 19, 9-12.
56. Shuey, D. J.; McCallus, D. E. and Giordano, T. (2002) RNAi: gene-silencing in therapeutic intervention. Drug Discov. Today 7 1040-1046.
57. Skorski, T.; Nieborowska-Skorska, M.; Nicolaides, N. C.; Szczylik, C.; Iversen, P.; Iozzo, R. V.; Zon, G. and Calabretta, B. (1994) Suppression of Philadelphia1 leukemia cell growth in mice by BCR-ABL antisense oligodeoxynucleotide. Proc. Natl. Acad. Sci. USA 91, 4504-4508.
58. Smetsers, T. F.; Skorski, T.; van de Locht, L.T.; Wessels, H. M.; Pennings, A. H.; de Witte, T.; Calabretta, B. and Mensink, E. J. (1994) Antisense BCR-ABL oligonucleotides induce apoptosis in the Philadelphia chromosome-positive cell line BV173. Leukemia 8, 129-140.
59. Sohail, M.; Doran, G.; Riedemann, J.; Macaulay, V. and Southern, E. M. (2003) A simple and cost-effective method for producing small interfering RNAs with high efficacy. Nucleic Acids Res. 31 e38.
60. Song, E.; Lee, S. K.; Wang, J.; Ince, N.; Ouyang, N.; Min, J.; Chen, J.; Shankar, P. and Lieberman, J. (2003) RNA interference targeting Fas protects mice from fulminant hepatitis. Nat. Med. 9, 347-351.
61. Stein, C. A. and Narayanan, R. (1994) Antisense oligodeoxynucleotides. Curr Opin Oncol. 6, 587-594.
62. Sterman, D. H.; Treat, J.; Litzky, L. A.; Amin, K. M.; Coonrod, L.; Molnar-Kimber, K.; Recio, A.; Knox, L.; Wilson, J. M.; Albelda, S. M. and Kaiser, L. R. (1998) Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: results of a phase I clinical trial in malignant mesothelioma. Hum. Gene Ther. 9, 1083-1092.
63. Sui, G.; Soohoo, C.; Affar el, B.; Gay, F.; Shi, Y. and Forrester, W. C. (2002) A DNA vector-based RNAi technology to suppress gene expression in mammalian cells. Proc. Natl. Acad. Sci. USA 99, 5515-5520.
64. Tiscornia, G.; Singer, O.; Ikawa, M. and Verma, I. M. (2003) A general method for gene knockdown in mice by using lentiviral vectors expressing small interfering RNA. Proc. Natl. Acad. Sci. USA 100 1844-1848.
65. van der Krol, A. R.; Mur, L. A.; Beld, M.; Mol, J. N. and Stuitje, A. R. (1990) Flavonoid genes in petunia: addition of a limited number of gene copies may lead to a suppression of gene expression. Plant Cell. 2, 291-299.
66. Volm, M. (1998) Multidrug resistance and its reversal. Anticancer Res. 18, 2905-2917.
67. Westbrook, C. A.; Hooberman, A. L.; Spino, C.; Dodge, R. K.; Larson, R. A.; Davey, F.; Wurster-Hill, D. H.; Sobol, R. E.; Schiffer, C. and Bloomfield, C. D. (1992) Clinical significance of the BCR-ABL fusion gene in adult acute lymphoblastic leukemia: a Cancer and Leukemia Group B Study (8762). Blood 80, 2983-2990.
68. Westin, P.; Stattin, P.; Damber, J. E. and Bergh, A. (1995) Castration therapy rapidly induces apoptosis in a minority and decreases cell proliferation in a majority of human prostatic tumors. Am. J. Pathol. 146, 1368-1375.
69. Wilda, M.; Fuchs, U.; Wossmann, W. and Borkhardt, A. (2002) Killing of leukemic cells with a BCR/ABL fusion gene by RNA interference (RNAi). Oncogene 21, 5716-5724.
70. Williams, B. R. (1997) Role of the double-stranded RNA-activated protein kinase (PKR) in cell regulation. Biochem. Soc. Trans. 25, 509-513.
71. Wohlbold, L.; van der Kuip, H.; Miething, C.; Vornlocher, H. P.; Knabbe, C.; Duyster, J. and Aulitzky, W. E. (2003) Inhibition of bcr-abl gene expression by small interfering RNA sensitizes for imatinib mesylate (STI571). Blood 102, 2236-2239.
72. Xu, Q. and Reed, J. C. (1998) Bax inhibitor-1, a mammalian apoptosis suppressor identified by functional screening in yeast. Mol. Cell. 1, 337-346.
73. Yang, D.; Buchholz, F.; Huang, Z.; Goga, A.; Chen, C.Y.; Brodsky, F. M. and Bishop, J. M. (2002) Short RNA duplexes produced by hydrolysis with Escherichia coli RNase III mediate effective RNA interference in mammalian cells. Proc. Natl. Acad. Sci. USA 99 9942-9947.
74. Yee, D.; McGuire, S. E.; Brunner, N.; Kozelsky, T. W.; Allred, D. C.; Chen, S. H. and Woo, S. L. (1996) Adenovirus-mediated gene transfer of herpes simplex virus thymidine kinase in an ascites model of human breast cancer. Hum. Gene Ther. 7, 1251-1257.
75. Yeh, S.; Kang, H. Y.; Miyamoto, H.; Nishimura, K.; Chang, H. C.; Ting, H. J.; Rahman, M.; Lin, H. K.; Fujimoto, N.; Hu, Y. C.; Mizokami, A.; Huang, K. E. and Chang, C. (1999) Differential induction of androgen receptor transactivation by different androgen receptor coactivators in human prostate cancer DU145 cells. Endocrine 11 195-202.
76. Yergeau, D. A.; Hetherington, C. J.; Wang, Q.; Zhang, P.; Sharpe, A. H.; Binder, M.; Marin-Padilla, M.; Tenen, D. G.; Speck, N. A. and Zhang, D. E. (1997) Embryonic lethality and impairment of haematopoiesis in mice heterozygous for an AML1-ETO fusion gene. Nat. Genet. 15, 303-306.
77. Zamore, P. D. (2002) Ancient pathways programmed by small RNAs. Science 296, 1265-1269.
78. Zeng, Y.; Yi, R. and Cullen, B. R. (2003) MicroRNAs and small interfering RNAs can inhibit mRNA expression by similar mechanisms. Proc. Natl. Acad. Sci. USA 100, 9779-9784.
79. Zhang, L.; Yang, N.; Mohamed-Hadley, A.; Rubin, S.C. and Coukos, G. (2003) Vector-based RNAi, a novel tool for isoform-specific knock-down of VEGF and anti-angiogenesis gene therapy of cancer. Biochem. Biophys. Res. Commun. 303, 1169-1178.
80. Zhang, W. W. (1999) Development and application of adenoviral vectors for gene therapy of cancer. Cancer Gene Ther. 6, 113-138.